GILD vs AMGN
GILD and AMGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | AMGNAmgen Inc. |
|---|---|---|
| Market cap | $162.93B | $209.26B |
| P/E (TTM) | 17.9 | 27.0 |
| P/B | 6.93 | 22.77 |
| P/S | 5.5x | 5.6x |
| Dividend yield | 2.46% | 2.45% |
| Revenue | $29.74B(TTM) | $37.22B(TTM) |
| Revenue growth (YoY) | 2.4% | 10.0% |
| Net income | $9.22B(TTM) | $7.80B(TTM) |
| Earnings growth (YoY) | 1672.9% | 88.5% |
| EPS, diluted | $7.35(TTM) | $14.37(TTM) |
| EBIT margin | 34.0% | 24.7% |
| ROE | 36.2% | 83.9% |
| ROIC | 21.6% | 15.3% |
| 1y total return | +15.6% | +29.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: GILD vs AMGN
| Metric | GILD | AMGN |
|---|---|---|
| End value | $20.4K | $35.2K |
| Total return | +104.0% | +251.7% |
| CAGR | +7.1% | +12.9% |
| Volatility | 25.7% | 24.8% |
| Sharpe | 0.25 | 0.46 |
| Sortino | 0.37 | 0.68 |
| Max drawdown | -36.0% | -24.9% |
Based on 2600 common trading days, 2016-03-29 → 2026-07-30 · risk-free 3.82% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)